LJPC-401 Drug Asset Due Diligence Report 2026

This LJPC-401 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 11 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether LJPC-401 can convert its Synthetic peptide profile and Hepc biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	LJPC-401 (query alias: LJPC-401)
Modality / target	Synthetic peptide; Hepc; Hepc stimulants
Highest global status	Phase 2
Originator	Atos SE
Active developers	La Jolla Pharmaceutical Co., Atos SE

The MCP disease footprint includes Anemia, Sickle Cell, Thalassemia, Iron Overload. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT03395704	Phase 2	Completed	70	Primary endpoint not disclosed in English source
NCT03381833	Phase 2	Terminated	84	Primary endpoint not disclosed in English source
ACTRN12617000689370	Not Applicable	Completed	36	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase 2, Multi-Center, Randomized, Placebo Controlled, Single-Blind Study With LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis

Phase 2; n=70; evaluation: Not stated in English source. Reported fields: Effect of LJPC-401 Versus Placebo on Blood Iron Levels(Mean) = -32.8 % ; Effect of LJPC-401 Versus Placebo on Blood Iron Levels(Mean) = -2.5 %

La Jolla to Reassess Continued Development of LJPC-401 Based on Recent Clinical Results

Phase 2; n=60; evaluation: Positive. Reported fields: TSAT = -33 % ; TSAT = -3 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

LJPC-401 addresses Anemia, Sickle Cell, Thalassemia, Iron Overload. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Synthetic peptide—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 4 matched transaction record(s) under the scope “target-level comparable: Hepc.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: Hepc records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-04-28	Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration	NDA/BLA	US$300.0M upfront
2017-02-27	ASKA to acquire an option to develop and commercialize Pieris’s PRS-080 for anemia in Japan and other Asian markets	Phase 1	US$2.8M upfront; US$80.0M milestones
2013-10-01	Protagonist Therapeutics entered into a Research Collaboration and License Agreement with Zealand Pharma A/S	Not disclosed	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO